Please assess the completion status of the following clinical trial:

Trial Title: Lornoxicam vs. Paracetamol After Lower Abdominal Surgery

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE4
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* lower abdominal surgery~Exclusion Criteria:~* body weight more than 150% of their ideal body weight~* history of significant cardiac, pulmonary, renal, hepatic or hematological disease; chronic drug or alcohol abuse; hypersensitivity to any of the studied drugs; bronchial asthma; gastritis or peptic ulcer; and pregnancy~* patients who received any analgesic drug a day before surgery

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 69 Years
- Healthy Volunteers: f

Study Arms:
- Lornoxicam (Type: EXPERIMENTAL): Lornoxicam 16 mg will be given at skin closure and 8 mg will be given 12 hours postoperatively
- Control (Type: PLACEBO_COMPARATOR): Patients will receive normal saline at skin closure, at 6, 12, 18 hours postoperatively.
- Paracetamol (Type: EXPERIMENTAL): 1 gm of paracetamol will be given at skin closure, 6, 12, 18 hours postoperatively

Based on this trial design, predict the completion outcome and termination type (if applicable).